Therapeutic Prospects of Gene Therapy for Atrial Fibrillation

Heart Lung and Circulation

Volumn 25, Issue 8, 2016, Pages 808-813

  Farraha, Melad ^c   Chong, James J H ^a,b,c   Kizana, Eddy ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Arrhythmia; Atrial fibrillation; Gene therapy; Heart; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; CALCIUM CHANNEL BLOCKING AGENT; CONNEXIN 40; CONNEXIN 43; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; L TYPE CALCIUM CHANNEL BLOCKING PROTEIN GEM; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PLASMID DNA; POTASSIUM CHANNEL BLOCKING AGENT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTERY PERFUSION; ATRIAL FIBRILLATION; ATRIOVENTRICULAR CONDUCTION; CARDIOVASCULAR PROCEDURE; CLINICAL EFFECTIVENESS; ELECTROPORATION; EPICARDIAL PAINTING; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE VECTOR; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM; HEART RATE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINUS RHYTHM; VIRUS GENOME; ANIMAL; GENE TRANSFER; GENETICS; PATHOPHYSIOLOGY; PROCEDURES; RISK FACTOR;

ANIMALS; ATRIAL FIBRILLATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; RISK FACTORS;

EID: 84973869923     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2016.04.011     Document Type: Review

References (43)

1. [1] Australia, N.H.F.o., Atrial Fibrillation Information Sheet, N.H.F.o. Australia, Editor. p. 1–8.
2. [2] Lake, F.R., et al. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 19:4 (1989), 321–326.
3. [3] Strokefoundation.com.au. New atrial fibrillation resource — National Stroke Foundation - Australia. 2014 [cited 2016 14th March 2016]; Available from: https://strokefoundation.com.au/media-releases/2015/05/26/new-atrial-fibrillation-resource.
4. [4] Kalman, J.M., et al. National Heart Foundation of Australia consensus statement on catheter ablation as a therapy for atrial fibrillation. Med J Aust 198:1 (2013), 27–28.
5. [5] PricewaterhouseCoopers, The Economic Costs of Atrial Fibrillation in Australia. 2010, National Stroke Foundation. p. 1–79.
6. [6] Mozaffarian, D., et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131:4 (2015), e29–e322.
7. [7] Chugh, S.S., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129:8 (2014), 837–847.
8. [8] Amit, G., et al. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation 121:21 (2010), 2263–2270.
9. [9] Bikou, O., et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 92:2 (2011), 218–225.
10. [10] Echt, D.S., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:12 (1991), 781–788.
11. [11] Zimetbaum, P., Antiarrhythmic drug therapy for atrial fibrillation. Circulation 125:2 (2012), 381–389.
12. [12] Haïssaguerre, M., et al. Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. New England Journal of Medicine 339:10 (1998), 659–666.
13. [13] Amerena, J.V., et al. Update on the management of atrial fibrillation. Med J Aust 199:9 (2013), 592–597.
14. [14] Verma, A., Atrial-fibrillation ablation should be considered first-line therapy for some patients. Curr Opin Cardiol 23:1 (2008), 1–8.
15. [15] Wilber, D.J., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA 303:4 (2010), 333–340.
16. [16] Bauer, A., et al. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation 110:19 (2004), 3115–3120.
17. [17] Lugenbiel, P., et al. Genetic suppression of Galphas protein provides rate control in atrial fibrillation. Basic Res Cardiol, 107(3), 2012, p265.
18. [18] Maeder, M.L., Gersbach, C.A., Genome-editing Technologies for Gene and Cell Therapy. Mol Ther 24:3 (2016), 430–446.
19. [19] French, B.A., et al. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 90:5 (1994), 2414–2424.
20. [20] Kizana, E., Alexander, I.E., Cardiac gene therapy: therapeutic potential and current progress. Curr Gene Ther 3:5 (2003), 418–451.
21. [21] Rincon, M.Y., VandenDriessche, T., Chuah, M.K., Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res 108:1 (2015), 4–20.
22. [22] Schmidt-Wolf, G.D., Schmidt-Wolf, I.G.H., Non-viral and hybrid vectors in human gene therapy: an update. Trends in Molecular Medicine 9:2 (2003), 67–72.
23. [23] Liu, Z., Donahue, J.K., The Use of Gene Therapy for Ablation of Atrial Fibrillation. Arrhythmia & Electrophysiology Review 3:3 (2014), 139–144.
24. [24] Kevin Donahue, J., et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 6:12 (2000), 1395–1398.
25. [25] Donahue, J.K., et al. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A 94:9 (1997), 4664–4668.
26. [26] Donahue, J.K., et al. Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther 5:5 (1998), 630–634.
27. [27] Karakikes, I., et al. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Mol Ther 20:3 (2012), 565–571.
28. [28] Nagata, K., et al. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol 33:3 (2001), 575–580.
29. [29] Roth, D.M., et al. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum Gene Ther 15:10 (2004), 989–994.
30. [30] Sasano, T., et al. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol 42:5 (2007), 954–961.
31. [31] Greener, I., Donahue, J.K., Gene therapy strategies for cardiac electrical dysfunction. J Mol Cell Cardiol 50:5 (2011), 759–765.
32. [32] Kikuchi, K., et al. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation 111:3 (2005), 264–270.
33. [33] Donahue, J.K., Biological Therapies for Atrial Fibrillation: Ready for Prime Time?. J Cardiovasc Pharmacol 67:1 (2016), 19–25.
34. [34] Hu, Y.-F., et al. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Science Translational Medicine, 6(245), 2014 p. 245ra94–245ra94.
35. [35] Aistrup, G.L., et al. Targeted nonviral gene-based inhibition of Galpha(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation. Heart Rhythm 8:11 (2011), 1722–1729.
36. [36] Trappe, K., et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J 34:2 (2013), 147–157.
37. [37] Li, J.J., et al. Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Cardiovasc Res 30:1 (1995), 97–105.
38. [38] Solheim, S., et al. Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction. Am Heart J, 155(1), 2008 p. 55.e1–9.
39. [39] Hargrave, B., et al. Electroporation-mediated gene transfer directly to the swine heart. Gene Ther 20:2 (2013), 151–157.
40. [40] Heist, E.K., Mansour, M., Ruskin, J.N., Rate Control in Atrial Fibrillation: Targets, Methods, Resynchronization Considerations. Circulation 124:24 (2011), 2746–2755.
41. [41] Boriani, G., et al. Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. Drugs 63:14 (2003), 1489–1509.
42. [42] Murata, M., et al. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ Res 95:4 (2004), 398–405.
43. [43] Igarashi, T., et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 125:2 (2012), 216–225.